Publication: Treatment with intrastromal and intracameral voriconazole in 2 eyes with lasiodiplodia theobromae keratitis : Case reports
1
Issued Date
2015-01-01
Resource Type
ISSN
15365964
00257974
00257974
Other identifier(s)
2-s2.0-84928583237
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Medicine (United States). Vol.94, No.6 (2015)
Suggested Citation
Kaevalin Lekhanont, Manachai Nonpassopon, Nutthida Nimvorapun, Pitak Santanirand Treatment with intrastromal and intracameral voriconazole in 2 eyes with lasiodiplodia theobromae keratitis : Case reports. Medicine (United States). Vol.94, No.6 (2015). doi:10.1097/MD.0000000000000541 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36653
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment with intrastromal and intracameral voriconazole in 2 eyes with lasiodiplodia theobromae keratitis : Case reports
Other Contributor(s)
Abstract
© 2015 Wolters Kluwer Health, Inc. To report the clinical presentation and the role of intrastromal and intracameral voriconazole injection in the management of rare cases of fungal keratitis caused by Lasiodiplodia theobromae. Two eyes of 2 patients with Lasiodiplodia keratitis unresponsive to topical and oral antifungal medications were included in this study. Diagnosis of Lasiodiplodia keratitis was confirmed by microbiological analysis, including culture-based (case 1 and 2) and DNA sequencing techniques (case 2 only). The first patient presented with multiple satellite lesions and one of these infiltrates spread deeply into the cornea, forming a stromal abscess. Another patient had a large full-thickness corneal infiltrates with several fungal balls in the anterior chamber, requiring a limbus-tolimbus therapeutic penetrating keratoplasty. Despite aggressive topical therapy, the stromal abscess continued to worsen in the first case and recurrent keratitis was observed postoperatively in the second case. Voriconazole 50mg/0.1mL was administered intracamerally and intrastromally around the fungal abscess as adjuncts to topical antimycotics in the first case. The second patient who needed therapeutic keratoplasty was treated with an intracameral injection of 50mg/0.1mL voriconazole at the end of surgery. Postoperatively, 100mg/0.1mL voriconazole was also injected intracamerally after the recurrence of infection was noted in the graft. Reinjections were given 48 hours apart in both cases. After the injections, all corneal and anterior chamber lesions were reduced in size and density and completely resolved within 4 weeks. Intrastromal and intracameral voriconazole injections may offer safe and effective treatment options for L theobromae keratitis.